文献速递肺结节与肺癌

部分实性肺腺癌淋巴结分期中FDG PET-CT诊断准确性的系统评价与Meta分析

Systematic Review and Meta-Analysis of 2-[18F]Fluoro-2-Deoxy-d-Glucose PET-CT Imaging for Nodal Staging of Part-Solid Lung Adenocarcinomas.
PubMed 文献 · Chest · 2026-08-06

该系统评价与Meta分析评估了FDG PET-CT对T1部分实性肺腺癌淋巴结分期的诊断准确性。结果显示淋巴结转移罕见,PET-CT敏感性低(28%)、特异性高(90%)、准确性差(0.599);与CT相比敏感性无显著差异,但CT特异性更高。≤10 mm结节未报告淋巴结转移。

要点

  • FDG PET-CT对部分实性肺腺癌淋巴结分期敏感性低(28%),准确性差(0.599)。
  • ≤10 mm(T1a)结节未报告淋巴结转移,提示PET-CT价值有限。

核心结论

  • FDG PET-CT对部分实性肺腺癌淋巴结分期诊断价值有限,尤其对≤10 mm结节。
  • CT与PET-CT敏感性无显著差异,但CT特异性更高。

研究设计与样本

  • 采用PICO框架进行系统检索,预设纳入排除标准,使用QUADAS-2评估偏倚风险。
  • 合并FDG PET-CT对T1部分实性肺腺癌淋巴结分期的敏感性与特异性,并与胸部CT比较。

主要发现

  • 6项研究报告淋巴结受累率为0%。
  • 4项研究显示FDG PET-CT敏感性28%、特异性90%、准确性0.599。
  • 2项研究报告总大小≤10 mm结节无淋巴结转移。

关键数值与推荐

  • FDG PET-CT淋巴结分期:敏感性28%,特异性90%,准确性0.599。
  • 总大小≤10 mm(T1a)结节未报告淋巴结转移。

临床怎么用

  • 对部分实性肺腺癌,尤其≤10 mm结节,应谨慎解读FDG PET-CT淋巴结分期结果。
  • CT可作为特异性更高的替代或补充手段,但需结合临床综合判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lung adenocarcinoma is the most prevalent subtype of lung cancer. When presenting as ground-glass or part-solid nodules, lung adenocarcinomas typically show slow growth, rarely metastasize, and have low 2-[18F]fluoro-2-deoxy-d-glucose (FDG) avidity. Retrospective evidence demonstrated limited value of FDG PET-CT scan staging in T1 part-solid lung cancers. The National Institute for Health and Care Excellence recommends FDG PET-CT imaging to confirm localized disease in patients eligible for radical treatment. RESEARCH QUESTION: To carry out a systematic review to establish the diagnostic accuracy of FDG PET-CT imaging for nodal staging in T1 part-solid lung cancers. STUDY DESIGN AND METHODS: A systematic search was conducted using the PICO (population, intervention, comparison, outcome) framework. Predefined inclusion and exclusion criteria were applied. Relevant data were extracted, and risk of bias was assessed using the QUADAS-2 tool. Sensitivity and specificity of FDG PET-CT imaging for nodal staging in T1 part-solid lung cancers were pooled, presented in forest plots and as an HSROC curve, and compared with the diagnostic performance of CT imaging of the thorax. The association between total nodule size and nodal staging was explored. RESULTS: Nodal metastases were rare, with 6 studies reporting 0% nodal involvement. Diagnostic performance metrics for FDG PET-CT imaging were available in 4 studies, which showed low sensitivity (28%), high specificity (90%), and poor accuracy (0.599). In 2 studies comparing CT and FDG PET-CT imaging, no significant difference in sensitivity was observed (sensitivity: CT imaging, 12%; FDG PET-CT imaging, 29%; P = .320), whereas CT imaging demonstrated higher specificity (specificity: CT imaging, 97%; FDG PET-CT imaging, 83%; P < .001). In addition, no nodal metastases were reported in nodules with a total size ≤ 10 mm in 2 studies. INTERPRETATION: Our results show that FDG PET-CT imaging has limited diagnostic value for nodal staging in part-solid lung cancers, particularly for small nodules (total size ≤ 10 mm, T1a), where nodal metastasis was not observed. Although sensitivity did not differ between CT and FDG PET-CT imaging, CT imaging provided higher specificity. CLINICAL TRIAL REGISTRATION: PROSPERO; No.: CRD420251135365; URL: www.crd.york.ac.uk/PROSPERO/.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Choy PM, Wong HYA, Lim EKS, et al. Systematic Review and Meta-Analysis of 2-[18F]Fluoro-2-Deoxy-d-Glucose PET-CT Imaging for Nodal Staging of Part-Solid Lung Adenocarcinomas. Chest. 2026. PMID: 42556560. doi:10.1016/j.chest.2026.06.070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。